Literature DB >> 20562628

Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia.

Robin Haring1, Sebastian E Baumeister, Henry Völzke, Marcus Dörr, Stephan B Felix, Heyo K Kroemer, Matthias Nauck, Henri Wallaschofski.   

Abstract

BACKGROUND: Earlier studies have suggested that total testosterone concentrations influence the lipid metabolism. Whether these concentrations are prospectively associated with an adverse lipid profile and an increased risk of incident dyslipidemia has not yet been investigated. METHODS AND
RESULTS: Our study population consisted of 1468 men, aged 20–79 years, who were repeatedly examined as part of the population-based Study of Health in Pomerania. Serum total testosterone concentrations measured by the chemiluminescent enzyme immunoassays were categorized into age-specific quartiles. We used generalized estimating equations models to assess the prospective association between total testosterone concentrations and lipid profile components including total cholesterol (TC), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride (TG) concentrations, as well as incident dyslipidemia after 5 years of follow-up. Multivariate models revealed that total testosterone concentrations in the lowest quartile were associated with higher TC and TG concentrations in both cross-sectional [TC: 0.23 mmol/l (95% confidence interval, CI, 0.02–0.42); TG: 0.73 mmol/l (95% CI, 0.53–0.94)] and longitudinal analyses [TC: 0.20 mmol/l (95% CI, 0.03–0.27); TG: 0.62 mmol/l (95% CI, 0.43–0.80)], but not with high-density lipoprotein cholesterol or low-density lipoprotein cholesterol concentrations. Baseline prevalence of dyslipidemia was 57.1% with a crude incidence rate of 46.6 per 1000 person-years. Total testosterone concentrations in the lowest quartile predicted dyslipidemia; age-adjusted relative risks (RR) for men in quartiles 1, 2, and 3 as compared to quartile 4 (highest, reference) were 1.28 (95% CI, 1.06–1.54), 1.10 (95% CI, 0.91–1.33), and 1.05 (95% CI, 0.86–1.29), respectively. This effect was particularly strong among men aged 20–39 years (relative risk, 1.51; 95% CI, 1.08–2.10).
CONCLUSION: Low total testosterone concentrations are prospectively associated with an adverse lipid profile and increased risk of incident dyslipidemia. These findings are particularly interesting and may contribute to an explanation for the higher cardiovascular disease risk in men with lower total testosterone concentrations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20562628     DOI: 10.1097/HJR.0b013e32833c1a8d

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  21 in total

1.  Relation between sex hormone concentrations, peripheral arterial disease, and change in ankle-brachial index: findings from the Framingham Heart Study.

Authors:  Robin Haring; Thomas G Travison; Shalender Bhasin; Ramachandran S Vasan; Henri Wallaschofski; Maithili N Davda; Andrea Coviello; Joanne M Murabito
Journal:  J Clin Endocrinol Metab       Date:  2011-09-21       Impact factor: 5.958

2.  Clinical correlates of sex steroids and gonadotropins in men over the late adulthood: the Framingham Heart Study.

Authors:  R Haring; V Xanthakis; A Coviello; L Sullivan; S Bhasin; H Wallaschofski; J M Murabito; R S Vasan
Journal:  Int J Androl       Date:  2012-05-29

Review 3.  Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis.

Authors:  Andre B Araujo; Julia M Dixon; Elizabeth A Suarez; M Hassan Murad; Lin T Guey; Gary A Wittert
Journal:  J Clin Endocrinol Metab       Date:  2011-08-03       Impact factor: 5.958

Review 4.  The role of testosterone therapy in cardiovascular mortality: culprit or innocent bystander?

Authors:  Monique S Tanna; Arthur Schwartzbard; Jeffery S Berger; Joseph Alukal; Howard Weintraub
Journal:  Curr Atheroscler Rep       Date:  2015-03       Impact factor: 5.113

Review 5.  Lipid effects of endocrine medications.

Authors:  Dan V Mihailescu; Avni Vora; Theodore Mazzone
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

6.  Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study.

Authors:  Robin Haring; Zhaoyang Teng; Vanessa Xanthakis; Andrea Coviello; Lisa Sullivan; Shalender Bhasin; Joanne M Murabito; Henri Wallaschofski; Ramachandran S Vasan
Journal:  Clin Endocrinol (Oxf)       Date:  2013-04       Impact factor: 3.478

7.  An update on testosterone, HDL and cardiovascular risk in men.

Authors:  Arthi Thirumalai; Katya B Rubinow; Stephanie T Page
Journal:  Clin Lipidol       Date:  2015

8.  Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study.

Authors:  Molly M Shores; Mary L Biggs; Alice M Arnold; Nicholas L Smith; W T Longstreth; Jorge R Kizer; Calvin H Hirsch; Anne R Cappola; Alvin M Matsumoto
Journal:  J Clin Endocrinol Metab       Date:  2014-03-14       Impact factor: 5.958

9.  Serum concentrations of p, p'-DDE, HCB, PCBs and reproductive hormones among men of reproductive age.

Authors:  Kelly K Ferguson; Russ Hauser; Larisa Altshul; John D Meeker
Journal:  Reprod Toxicol       Date:  2012-05-05       Impact factor: 3.143

10.  Sex-specific genetic effects across biomarkers.

Authors:  Emily Flynn; Yosuke Tanigawa; Fatima Rodriguez; Russ B Altman; Nasa Sinnott-Armstrong; Manuel A Rivas
Journal:  Eur J Hum Genet       Date:  2020-09-01       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.